EGFR Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational Study-Reference-Cited by-同舟云学术

EGFR Mutation Status and First-Line Treatment in Patients with Stage III/IV Non–Small Cell Lung Cancer in Germany: An Observational Study

Published:2015-06-12 Issue:8 Volume:24 Page:1254-1261
ISSN:1055-9965
Container-title:Cancer Epidemiology Biomarkers & Prevention
language:en
Short-container-title:Cancer Epidemiol Biomarkers Prev

Author:

Schuette Wolfgang,Schirmacher Peter,Eberhardt Wilfried Ernst Erich,Fischer Juergen R.,von der Schulenburg J.-Matthias Graf,Mezger Joerg,Schumann Christian,Serke Monika,Zaun Silke,Dietel Manfred,Thomas Michael

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology,Epidemiology

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world evidence reported for clinical efficacy evaluation in European Public Assessment Reports of authorised targeted therapies for solid malignancies: a comprehensive review (2018-2022);ESMO Real World Data and Digital Oncology;2024-06

2. Background of the need for targeted therapy options and platinum-based therapy responses in EGFR and ALK-mutated lung adenocarcinoma;Turkish Journal of Clinics and Laboratory;2023-09-30

3. State of the Art: onkogen alteriertes nichtkleinzelliges Lungenkarzinom im Stadium IV;Die Onkologie;2022-10-25

4. Association between epidermal growth factor receptor gene mutation status and short‑term efficacy of first‑line platinum‑containing chemotherapy in advanced non‑small cell lung cancer;Biomedical Reports;2022-05-11

5. RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC;JTO Clinical and Research Reports;2022-04